Atopic dermatitis model non-human animal and use thereof
a technology for atopic dermatitis and non-human animals, applied in the field of atopic dermatitis model non-human animals, can solve the problems of increased scratching behavior and severe dermatitis
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
Problems solved by technology
Method used
Image
Examples
first embodiment
[0131]In one embodiment, the present invention provides a method for screening the therapeutic agent for atopic dermatitis, which includes a step of quantitative measurements of scratching behavior of the above-described atopic dermatitis model non-human animal under administration of a test substance; and determination that the test substance is the therapeutic agent for atopic dermatitis in a case where the quantitatively determined degree of the scratching behavior is decreased, compared to the degree of scratching behavior in the absence of the test substance administration.
[0132]The scratching behavior can not be evaluated at a cell level, and thus needs to be evaluated at an individual level. As described above, the above-described atopic dermatitis model non-human animal shows extremely similar symptoms as those of the human atopic dermatitis. For this reason, by the method for screening of the present embodiment, it is possible to efficiently screen a therapeutic agent effec...
second embodiment
[0137]In one embodiment, the present invention provides a method for screening the therapeutic agent for atopic dermatitis, which includes a step of stimulating the TCR of the CD4+ T cells from a patient with atopic dermatitis, DOCK8− / − CD4+ T cells or MST1− / − CD4+ T cells in the presence of the test substance to quantitatively compare the expression level of the IL-31 by the CD4+ T cells; and determining that the test substance is the therapeutic agent for atopic dermatitis in a case where the expression level of the IL-31 is decreased compared to that in the absence of the test substance.
[0138]The expression level of the IL-31 may be quantitatively determined at a transcription level by, for example, quantitative real-time PCR or the like, or may be quantitatively measured at a protein level by, for example, an ELISA method or the like.
[0139]As will be described in the examples later, if the TCR of the CD4+ T cells from the patient with the atopic dermatitis, DOCK8− / − CD4+ T cells...
third embodiment
[0142]In one embodiment, the present invention provides a method for screening the therapeutic agent for atopic dermatitis, which includes a step of expressing the EPAS1 gene in T cells in the presence of the test substance to quantitatively compare the expression level of IL-31; and determining that the test substance is the therapeutic agent for atopic dermatitis in a case where the expression level is decreased compared to the level in the absence of the test substance.
[0143]As will be described in the examples later, if the EPAS1 gene is overexpressed in the CD4+ T cells, the expression level of IL-31 is increased. Therefore, the substance that suppresses the increase in the expression level of IL-31 is a candidate therapeutic agent for atopic dermatitis. In other words, the therapeutic agent for atopic dermatitis can also be called an IL-31 expression inhibitor.
[0144]The T cells may be primary T cells, may be an established T cell line, or may be a thymocyte cell line.
PUM
| Property | Measurement | Unit |
|---|---|---|
| body weight | aaaaa | aaaaa |
| body weight | aaaaa | aaaaa |
| body weight | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More